3.

Univariate and multivariate analyses of OS

Characteristics	Univariate analysis			Multivariate analysis
	HR (95% CI)	P		HR (95% CI)	P
OS, overall survival; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; SUVmax, the maximum standardized uptake values; SUVmean, mean standardized uptake values; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HR, hazard ratio; 95% CI, 95% confidence interval.
Age (<60vs. ≥60 years)	0.90 (0.86−1.56)	0.722
Sex (male vs. female)	0.94 (0.49−1.80)	0.852
Lauren’s classification (diffused vs. undiffused)	1.31 (0.68−2.53)	0.403
Lymph node metastasis (no vs. yes)	1.70 (0.77−3.80)	0.150
T stage (T2/T3 vs. T4)	1.79 (1.12−2.87)	0.005		2.33 (1.21−4.51)	0.012
Histologic grade (poorly vs. moderately-poorly or Moderately)	0.41 (0.18−0.97)	0.029		0.39 (0.17−0.94)	0.035
Neoadjuvant chemotherapy (no vs. yes)	1.35 (0.76−2.41)	0.289
Surgery (subtotal gastrectomy vs. total gastrectomy)	1.05 (0.60−1.82)	0.873
Lymph node dissection (D1 vs. D0)	1.35 (0.42−4.35)	0.601
HER2 expression (positive vs. negative)	0.74 (0.38−1.44)	0.37
Ki-67 expression (≥75% vs. <75%)	1.17 (0.62−2.21)	0.614
c-Met expression (positive vs. negative)	0.50 (0.19−1.28)	0.128
EGFR expression (positive vs. negative)	0.95 (0.49−1.86)	0.887
SUVmax (<10.9vs. ≥10.9)	0.45 (0.16−1.25)	0.106
SUVmean (<5.9vs. ≥5.9)	0.44 (0.14−1.40)	0.139
MTV (<15.1 cm3 vs. ≥15.1 cm3)	1.79 (1.01−3.18)	0.037		1.21 (0.45−3.26)	0.701
TLG (<47.3 cm3 vs. ≥47.3 cm3)	1.90 (1.05−3.45)	0.028		2.10 (1.13−3.89)	0.019